Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of ...

Credit: Tonix Pharmaceuticals. Tonmya is a once-daily sublingual tablet of cyclobenzaprine HCI taken at bedtime for the treatment of fibromyalgia. Clinical trials have demonstrated that Tonmya reduces ...

Add Yahoo as a preferred source to see more of our stories on Google. A close up of white woman's wrist, which she's holding as if experiencing pain or joint stiffness. She's sitting on a grey couch ...

Fibromyalgia patients’ satisfaction with their treatment is predictable through consideration of pre-treatment, patient-specific factors, according to a study in the journal Clinical and Experimental ...

The Quell ® neuromodulation device (NeuroMetrix) has received the Food and Drug Administration De Novo authorization for use as an aid in reducing the symptoms of fibromyalgia in adults with high pain ...

Dear Doctors: I had muscle pain and exhaustion for two years, and no one could figure out what was wrong. A rheumatologist recently diagnosed me with fibromyalgia. I would appreciate any information ...

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in more than 15 years. (HealthDay News) — The U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine ...

Many people with fibromyalgia describe the chronic condition as a "bad case of the flu that never goes away," because they have widespread pain, wake up with stiff muscles and experience brain fog, ...

There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska ...

The main market opportunities in fibromyalgia therapeutics include the significant number of anticipated cases in India by 2029, a limited treatment landscape with few approved drugs and generics ...

Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data ...